Developments in 177Lu-based radiopharmaceutical therapy and dosimetry
177Lu is a radioisotope that has become increasingly popular as a therapeutic agent for
treating various conditions, including neuroendocrine tumors and metastatic prostate …
treating various conditions, including neuroendocrine tumors and metastatic prostate …
Administering [177Lu] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer (LuTectomy): a single-centre, single-arm, phase 1/2 …
Background High-risk localised prostate cancer (HRCaP) has high rates of biochemical
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …
recurrence;[177 Lu] Lu-PSMA-617 is effective in men with advanced prostate cancer …
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
RS Eapen, SG Williams, S Macdonald… - Nature Reviews …, 2024 - nature.com
High-risk localized prostate cancer remains a lethal disease with high rates of recurrence,
metastases and death, despite attempts at curative local treatment including surgery …
metastases and death, despite attempts at curative local treatment including surgery …
Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Background and objective: Innovations have improved outcomes in advanced prostate
cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …
cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that …
Tumor dosimetry using 177Lu: influence of background activity, measurement method and reconstruction algorithm
PF Staanum - EJNMMI physics, 2023 - Springer
Background Image-based tumor dosimetry after radionuclide therapy, using the isotope
177Lu, finds application eg, for tumor-to-organ dose comparison and for dose response …
177Lu, finds application eg, for tumor-to-organ dose comparison and for dose response …
Lesion dosimetry for [177Lu] Lu-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in patients with oligometastatic castration …
A single-institution prospective pilot clinical trial was performed to demonstrate the feasibility
of combining [177Lu] Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic …
of combining [177Lu] Lu-PSMA-617 radiopharmaceutical therapy (RPT) with stereotactic …
Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives
In light of widely expanding personalized medicine applications and their impact on clinical
outcomes, it is naturally befitting to explore all the dimensional aspects of personalized …
outcomes, it is naturally befitting to explore all the dimensional aspects of personalized …
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
Abstract 177 Lu radiopharmaceutical therapy is a standardized systemic treatment, with a
typical dose of 7.4 GBq per injection, but its response varies from patient to patient …
typical dose of 7.4 GBq per injection, but its response varies from patient to patient …
A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer
Simple Summary Metastatic prostate cancer has traditionally been treated with a
combination of hormonal and chemotherapy regimens. With the recent FDA approval of …
combination of hormonal and chemotherapy regimens. With the recent FDA approval of …
Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients
H Siebinga, BM Privé, SMB Peters… - CPT …, 2023 - Wiley Online Library
Studies to evaluate and optimize [177Lu] Lu‐PSMA treatment focus primarily on individual
patient data. A population pharmacokinetic (PK) dosimetry model was developed to explore …
patient data. A population pharmacokinetic (PK) dosimetry model was developed to explore …